Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Antibody and Peptide Therapeutics

Kerry Chester's Biography



Kerry Chester, Professor, University College London

Professor Kerry Chester leads the Recombinant Antibody Therapeutics Group at the UCL Cancer Institute (http://www.ucl.ac.uk/cancer/). Her main research interests are design and construction of antibody-based therapeutics and the interaction of these molecules with specific cancer targets. The work is largely translational and aimed at developing new agents for clinical use. To facilitate this, her group has established an academic GMP facility to make clinical grade recombinant proteins for use in First-in-Man and Phase I/II cancer trials. Kerry’s current research includes developing antibodies as cancer imaging agents, as therapeutic fusion proteins and to target novel nanomedicines.

Kerry Chester Image

Bench to Bedside with Pichia: Recombinant Antibody-Based Cancer Treatments

Wednesday, 20 July 2011 at 09:30

Add to Calendar ▼2011-07-20 09:30:002011-07-20 10:30:00Europe/LondonBench to Bedside with Pichia: Recombinant Antibody-Based Cancer TreatmentsSELECTBIOenquiries@selectbiosciences.com

Successful application of the Pichia pastoris expression system for production of recombinant clinical grade antibody-based therapeutics.


Add to Calendar ▼2011-07-20 00:00:002011-07-21 00:00:00Europe/LondonAntibody and Peptide TherapeuticsSELECTBIOenquiries@selectbiosciences.com